John McCall

President, PharMac LLC

United States of America

John McCall’s expertise is drug discovery, risk minimization, and medicinal chemistry. He has worked in a number of disease areas including acute and chronic neurologic disorders, psychiatric diseases, neuromuscular disease, cardiovascular disease, inflammatory disease, and oncology. He is currently President, PharMac LLC.
He began his career as a medicinal chemist with Upjohn and has subsequently held positions with Upjohn, Pharmacia and Upjohn, Pharmacia, and Pfizer.

John was Director of CNS Research with Upjohn, Vice President and Global Head of Chemistry for both Pharmacia and Pharmacia&Upjohn and Vice President Research with Pfizer. John chaired a NINDS development team in the spinal muscular atrophy area. He is a member of the NIH Blueprint Steering Committee and serves as a member of the NIH NeuroNEXT Steering Committee.

He is a member of thirteen administrative and scientific advisory boards, he consults and works with one venture capital funds, and has co-founded Reveragen (a company that is targeting new therapies for muscular dystrophy) and Imago (a company that is investigating epigenetic approaches to AML therapies).

His Board and Scientific Advisory Board work include positions with NINDS Blueprint, IRSF Foundation, Psychogenics, Byrrilium Bioscience, N.imbus, CeeTox, Lycera, Synergenics,  CINRG, Reaction Biology, ReveraGen Biopharma,and PharmOptima, Atlas, Ataxion, Emerald,

He has equity positions in Reveragen, Imago, Reaction Biology, Armune,  Apjohn, Verseon, Lycera, Psychogenics, Nimbus, Ataxion, Lilly, and Zoetis.

He holds over 53 US patents and over 74 refereed publications.